PhD in Oncology

Dalian Medical University (DMU), established in 1947 in the coastal city of Dalian, is one of China’s long-standing medical institutions, offering medicine, dentistry, nursing and allied health programs. With about 14,000 students and roughly 1,300 international students, DMU operates modern teaching and research facilities alongside multiple affiliated hospitals to provide clinically focused education and extensive practical experience.

DMU was among the early Chinese universities to offer MBBS programs in English and its medical degrees are recognized internationally. The university maintains state-of-the-art laboratories, a comprehensive library and three affiliated hospitals with significant bed capacity, ensuring hands-on clinical training and research exposure. DMU offers a wide portfolio of programs across health and related disciplines to prepare graduates for global medical careers.

Campus life is calm and study-oriented, with two main campuses, student clubs, exchange opportunities and support services for international students. On-campus apartments for international students are fully equipped and cost an estimated 11,000 RMB per year, while off-campus options vary by budget and location. For aspiring clinicians and health researchers, DMU combines rigorous training, hospital partnerships and a livable coastal setting to support professional development.

The PhD in Oncology at Dalian Medical University is for students who want to specialize in cancer research and treatment. This 3-year PhD program is taught in English and provides students with advanced knowledge of oncology.

The curriculum includes subjects like cancer biology, oncogenomics, and cancer therapeutics. Students will develop skills in research, data analysis, and experimental design through hands-on components like laboratory experiments and clinical trials.

Graduates can pursue careers as Oncologists, Cancer Researchers, Clinical Trial Coordinators, or Medical Writers. They can work in hospitals, research institutions, or pharmaceutical companies, helping to develop new cancer treatments and improve patient care.